TESARO (TSRO) Misses Q2 EPS by 37c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. AMZN
2. INTC
3. RDDT
4. COIN
5. PINS
6. FSLR
7. SBUX
8. DASH
9. SYK
10. FND

Go back to TESARO (TSRO) Misses Q2 EPS by 37c

TESARO Announces Second-Quarter 2015 Operating Results

August 6, 2015 4:02 PM EDT

U.S. FDA PDUFA action date for oral rolapitant is September 5, 2015 Bioequivalence of IV and oral rolapitant successfully demonstrated Data from Phase 3 NOVA trial of niraparib anticipated in Q4 2015 Cash and cash equivalents totaled $354 million as of June 30, 2015

WALTHAM, Mass., Aug. 6, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today reported operating results for second-quarter 2015 and provided an update on the Company's development programs.

"TESARO continues to make significant progress in advancing its... More